London · Delayed Price · Currency is GBP · Price in GBX 4basebio Statistics
Total Valuation
4basebio has a market cap or net worth of GBP 84.22 million. The enterprise value is 93.28 million.
| Market Cap | 84.22M |
| Enterprise Value | 93.28M |
Important Dates
The next estimated earnings date is Tuesday, December 29, 2026.
| Earnings Date | Dec 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
4basebio has 15.54 million shares outstanding. The number of shares has increased by 7.11% in one year.
| Current Share Class | 15.54M |
| Shares Outstanding | 15.54M |
| Shares Change (YoY) | +7.11% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 11.74% |
| Owned by Institutions (%) | 39.43% |
| Float | 5.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 111.91 |
| PB Ratio | 68.77 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 123.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.98, with a Debt / Equity ratio of 18.18.
| Current Ratio | 5.98 |
| Quick Ratio | 5.17 |
| Debt / Equity | 18.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -17.99 |
Financial Efficiency
Return on equity (ROE) is -177.98% and return on invested capital (ROIC) is -36.56%.
| Return on Equity (ROE) | -177.98% |
| Return on Assets (ROA) | -33.59% |
| Return on Invested Capital (ROIC) | -36.56% |
| Return on Capital Employed (ROCE) | -70.96% |
| Weighted Average Cost of Capital (WACC) | 7.58% |
| Revenue Per Employee | 5,579 |
| Profits Per Employee | -128,750 |
| Employee Count | 140 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.57 |
Taxes
| Income Tax | -550,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.68% in the last 52 weeks. The beta is 0.81, so 4basebio's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -28.68% |
| 50-Day Moving Average | 516.57 |
| 200-Day Moving Average | 525.85 |
| Relative Strength Index (RSI) | 49.72 |
| Average Volume (20 Days) | 1,686 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, 4basebio had revenue of GBP 781,000 and -18.03 million in losses. Loss per share was -1.16.
| Revenue | 781,000 |
| Gross Profit | 407,000 |
| Operating Income | -17.20M |
| Pretax Income | -18.58M |
| Net Income | -18.03M |
| EBITDA | -16.30M |
| EBIT | -17.20M |
| Loss Per Share | -1.16 |
Balance Sheet
The company has 14.05 million in cash and 23.11 million in debt, with a net cash position of -9.06 million or -0.58 per share.
| Cash & Cash Equivalents | 14.05M |
| Total Debt | 23.11M |
| Net Cash | -9.06M |
| Net Cash Per Share | -0.58 |
| Equity (Book Value) | 1.27M |
| Book Value Per Share | 0.08 |
| Working Capital | 14.36M |
Cash Flow
In the last 12 months, operating cash flow was -15.84 million and capital expenditures -1.23 million, giving a free cash flow of -17.06 million.
| Operating Cash Flow | -15.84M |
| Capital Expenditures | -1.23M |
| Depreciation & Amortization | 895,000 |
| Net Borrowing | 5.82M |
| Free Cash Flow | -17.06M |
| FCF Per Share | -1.10 |
Margins
| Gross Margin | 52.11% |
| Operating Margin | -2,201.92% |
| Pretax Margin | -2,378.36% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
4basebio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.11% |
| Shareholder Yield | -7.11% |
| Earnings Yield | -20.62% |
| FCF Yield | -19.52% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for 4basebio is 1,400.00, which is 158.30% higher than the current price. The consensus rating is "Buy".
| Price Target | 1,400.00 |
| Price Target Difference | 158.30% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 106.92% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
4basebio has an Altman Z-Score of -2.33 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.33 |
| Piotroski F-Score | 1 |